Adma Biologics earnings were $169.0M for the trailing 12 months ending Jun 30, 2026, with -18.2% growth year over year. The latest ADMA earnings report on Jun 30, 2026 announced Q2 2026 earnings of $37.8M, down 16.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ADMA reported annual earnings of $146.9M, with -25.7% growth.
ADMA past earnings growth
How has ADMA's earnings growth performed historically?
On ADMA's earnings call on Aug 5, 2026, Adma Biologics (NASDAQ: ADMA) reported Q2 2026 earnings per share (EPS) of $0.17, up 21.43% year over year. Total ADMA earnings for the quarter were $37.82 million. In the same quarter last year, Adma Biologics's earnings per share (EPS) was $0.14.
As of the last Adma Biologics earnings report, Adma Biologics is currently profitable. Adma Biologics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $168.96 million, a 19.13% decrease year over year.
What was ADMA's earnings growth in the past year?
As of Adma Biologics's earnings date in Aug 5, 2026, Adma Biologics's earnings has grown -18.18% year over year. This is 33.59 percentage points lower than the US Biotechnology industry earnings growth rate of 15.41%. ADMA earnings in the past year totalled $168.96 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.